- Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer. 2018 Academic Article GET IT
- Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer. 2018 Academic Article GET IT
Efficacy of the PARP inhibitor veliparib with carboplatin or as a single agent in patients with germline BRCA1- or BRCA2-associated metastatic breast cancer: California Cancer Consortium trial NCT01149083.
Clinical Cancer Research.
Times cited: 10
Grading dermatologic adverse events of cancer treatments: The common terminology criteria for adverse events version 4.0.
Journal of the American Academy of Dermatology.
Times cited: 81